![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dichloroethane | increases expression | EXP | | 6480464 | ethylene dichloride results in increased expression of ALS2CL mRNA | CTD | PMID:28189721, PMID:28960355 | 1,2-dimethylhydrazine | affects expression | EXP | | 6480464 | 1, 2-Dimethylhydrazine affects the expression of ALS2CL mRNA | CTD | PMID:22206623 | 2,2',4,4'-Tetrabromodiphenyl ether | increases expression | ISO | RGD:1305208 | 6480464 | 2 more ... | CTD | PMID:27291303 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:1605837 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of ALS2CL mRNA | CTD | PMID:22903824 | 2-hydroxypropanoic acid | increases expression | ISO | RGD:1605837 | 6480464 | Lactic Acid results in increased expression of ALS2CL mRNA | CTD | PMID:30851411 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:1605837 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of ALS2CL mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | multiple interactions | ISO | RGD:1605837 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of ALS2CL mRNA | CTD | PMID:28628672 | 4,4'-sulfonyldiphenol | increases expression | EXP | | 6480464 | bis4-hydroxyphenylsulfone results in increased expression of ALS2CL mRNA | CTD | PMID:30951980 | adefovir pivoxil | increases expression | ISO | RGD:1605837 | 6480464 | adefovir dipivoxil results in increased expression of ALS2CL mRNA | CTD | PMID:25596134 | aflatoxin B1 | increases expression | EXP | | 6480464 | Aflatoxin B1 results in increased expression of ALS2CL mRNA | CTD | PMID:19770486 | benzo[a]pyrene | decreases methylation | ISO | RGD:1605837 | 6480464 | Benzoapyrene results in decreased methylation of ALS2CL 5' UTR | CTD | PMID:27901495 | benzo[a]pyrene | affects methylation | ISO | RGD:1605837 | 6480464 | Benzoapyrene affects the methylation of ALS2CL promoter | CTD | PMID:27901495 | bisphenol A | decreases expression | ISO | RGD:1305208 | 6480464 | bisphenol A results in decreased expression of ALS2CL mRNA | CTD | PMID:25181051 | bisphenol A | affects expression | ISO | RGD:1305208 | 6480464 | bisphenol A affects the expression of ALS2CL mRNA | CTD | PMID:30816183 | bromobenzene | increases expression | ISO | RGD:1305208 | 6480464 | bromobenzene results in increased expression of ALS2CL mRNA | CTD | PMID:32479839 | C60 fullerene | increases expression | ISO | RGD:1305208 | 6480464 | fullerene C60 results in increased expression of ALS2CL mRNA | CTD | PMID:19167457 | calcitriol | multiple interactions | ISO | RGD:1605837 | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of ALS2CL mRNA | CTD | PMID:21592394 | calcitriol | increases expression | ISO | RGD:1605837 | 6480464 | Calcitriol results in increased expression of ALS2CL mRNA | CTD | PMID:21592394, PMID:26485663 | carbon nanotube | increases expression | EXP | | 6480464 | Nanotubes, Carbon results in increased expression of ALS2CL mRNA | CTD | PMID:25620056 | carbon nanotube | decreases expression | EXP | | 6480464 | Nanotubes more ... | CTD | PMID:25554681 | chloroacetaldehyde | affects expression | ISO | RGD:1605837 | 6480464 | chloroacetaldehyde affects the expression of ALS2CL mRNA | CTD | PMID:25596134 | chrysene | increases expression | EXP | | 6480464 | chrysene results in increased expression of ALS2CL mRNA | CTD | PMID:26377693 | cidofovir anhydrous | affects expression | ISO | RGD:1605837 | 6480464 | Cidofovir affects the expression of ALS2CL mRNA | CTD | PMID:25596134 | cisplatin | affects expression | ISO | RGD:1605837 | 6480464 | Cisplatin affects the expression of ALS2CL mRNA | CTD | PMID:25596134 | cisplatin | increases expression | ISO | RGD:1605837 | 6480464 | Cisplatin results in increased expression of ALS2CL mRNA | CTD | PMID:27392435 | cisplatin | multiple interactions | ISO | RGD:1605837 | 6480464 | [Cisplatin co-treated with jinfukang] results in increased expression of ALS2CL mRNA | CTD | PMID:27392435 | clodronic acid | affects expression | ISO | RGD:1605837 | 6480464 | Clodronic Acid affects the expression of ALS2CL mRNA | CTD | PMID:25596134 | cobalt dichloride | increases expression | ISO | RGD:1305208 | 6480464 | cobaltous chloride results in increased expression of ALS2CL mRNA | CTD | PMID:24386269 | copper(II) sulfate | increases expression | ISO | RGD:1605837 | 6480464 | Copper Sulfate results in increased expression of ALS2CL mRNA | CTD | PMID:19549813 | cyclosporin A | increases expression | ISO | RGD:1605837 | 6480464 | Cyclosporine results in increased expression of ALS2CL mRNA | CTD | PMID:25596134, PMID:27989131 | dexamethasone | multiple interactions | ISO | RGD:1605837 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of ALS2CL mRNA | CTD | PMID:28628672 | dioxygen | decreases expression | ISO | RGD:1605837 | 6480464 | Oxygen deficiency results in decreased expression of ALS2CL mRNA | CTD | PMID:25596134 | doxorubicin | decreases expression | ISO | RGD:1605837 | 6480464 | Doxorubicin results in decreased expression of ALS2CL mRNA | CTD | PMID:29803840 | elemental selenium | increases expression | ISO | RGD:1605837 | 6480464 | Selenium results in increased expression of ALS2CL mRNA | CTD | PMID:19244175 | ethanol | increases expression | EXP | | 6480464 | Ethanol results in increased expression of ALS2CL mRNA | CTD | PMID:30319688 | flutamide | increases expression | ISO | RGD:1305208 | 6480464 | Flutamide results in increased expression of ALS2CL mRNA | CTD | PMID:24136188 | ifosfamide | affects expression | ISO | RGD:1605837 | 6480464 | Ifosfamide affects the expression of ALS2CL mRNA | CTD | PMID:25596134 | indometacin | multiple interactions | ISO | RGD:1605837 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis4-hydroxyphenylsulfone] results in decreased expression of ALS2CL mRNA | CTD | PMID:28628672 | leflunomide | increases expression | ISO | RGD:1305208 | 6480464 | leflunomide results in increased expression of ALS2CL mRNA | CTD | PMID:24136188 | methamphetamine | increases expression | EXP | | 6480464 | Methamphetamine results in increased expression of ALS2CL mRNA | CTD | PMID:26307267 | methapyrilene | decreases expression | ISO | RGD:1305208 | 6480464 | Methapyrilene results in decreased expression of ALS2CL mRNA | CTD | PMID:30467583 | orphenadrine | affects expression | ISO | RGD:1305208 | 6480464 | Orphenadrine affects the expression of ALS2CL mRNA | CTD | PMID:23665939 | oxaliplatin | decreases expression | ISO | RGD:1305208 | 6480464 | oxaliplatin results in decreased expression of ALS2CL mRNA | CTD | PMID:25729387 | oxaliplatin | multiple interactions | ISO | RGD:1305208 | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of ALS2CL mRNA | CTD | PMID:25729387 | pirinixic acid | increases expression | EXP | | 6480464 | pirinixic acid results in increased expression of ALS2CL mRNA | CTD | PMID:18301758, PMID:18445702 | rac-lactic acid | increases expression | ISO | RGD:1605837 | 6480464 | Lactic Acid results in increased expression of ALS2CL mRNA | CTD | PMID:30851411 | selenium atom | increases expression | ISO | RGD:1605837 | 6480464 | Selenium results in increased expression of ALS2CL mRNA | CTD | PMID:19244175 | testosterone | multiple interactions | ISO | RGD:1605837 | 6480464 | [Testosterone co-treated with Calcitriol] results in increased expression of ALS2CL mRNA | CTD | PMID:21592394 | testosterone | increases expression | ISO | RGD:1605837 | 6480464 | Testosterone results in increased expression of ALS2CL mRNA | CTD | PMID:21592394 | tetraphene | affects expression | EXP | | 6480464 | benzaanthracene affects the expression of ALS2CL mRNA | CTD | PMID:26377693 | topotecan | decreases expression | ISO | RGD:1305208 | 6480464 | Topotecan results in decreased expression of ALS2CL mRNA | CTD | PMID:25729387 | topotecan | multiple interactions | ISO | RGD:1305208 | 6480464 | [oxaliplatin co-treated with Topotecan] results in decreased expression of ALS2CL mRNA | CTD | PMID:25729387 | valdecoxib | increases expression | ISO | RGD:1305208 | 6480464 | valdecoxib results in increased expression of ALS2CL mRNA | CTD | PMID:24136188 | valproic acid | increases methylation | ISO | RGD:1605837 | 6480464 | Valproic Acid results in increased methylation of ALS2CL gene | CTD | PMID:29154799 | zoledronic acid | increases expression | ISO | RGD:1605837 | 6480464 | zoledronic acid results in increased expression of ALS2CL mRNA | CTD | PMID:24714768, PMID:25596134 | |